Cellestive: Flexible Pathways Toward Antibody Discovery
Start with any source of immune B-cells and use Cellestive to get to a vetted sequence in just 6 weeks.

Unlocking the Full Potential of B-Cells
Three key immune hosts — conventional mice, and human-antibody-producing transgenic mice or rats — have been at the center of a vast majority of therapeutic antibodies approved to-date.
That’s why we designed Cellestive to harness the inherent power of immune B-cells. Through parallel hybridoma, memory B-cell, and plasma B-cell discovery pathways, we can capitalize fully on the proven advantages they can offer in a broad range of therapeutic discovery projects.
Vast Diversity
The complexity and diversity of the natural immune system can be captured through the use of various hosts and immunization strategies.
Affinity Maturation
The host immune system naturally refines antibodies over time, leading directly to higher affinity and stability.
High Specificity
Animal-derived antibodies exhibit both high specificity for the target antigen and lower cross-reactivity to self-antigens.
Enhanced Developability
Antibodies from natural immune systems exhibit more favorable bio-physical properties, which can help close the gap from "candidate" to "product."
Reach Higher, Climb Faster
Cellestive puts a truly stellar constellation of expertise and capabilities to work on your behalf. Get started with an introduction now.
Interrogate Whole Populations, Efficiently and Effectively
The more challenging your target, the more critical it becomes to secure a deep, comprehensive set of antigen-specific antibodies. That’s precisely what we deliver your project through our Cellestive platform.
Get More Hits on Target
By pursuing hybridoma, memory B-cell, and plasma B-cell discovery pathways in parallel, we efficiently generate distinct candidate sets, freeing you from the innate limitations or biases present in any one of these pathways. Simply put, with Cellestive, you don’t have to sacrifice any single variable — specificity, diversity, affinity, etc. — in favor of another. Instead, the entire population is open to interrogation, yielding a deep pool of opportunities through streamlined processes that happen in unison, rather than in a back-to-back, serial fashion.
.jpeg)
Screen Thoroughly and Rapidly
With a full immune repertoire at your disposal from any cell secreting an antibody, Cellestive makes merging sequence-based and function-based antibody screening possible. We combine output with paired heavy- and light-chain sequence recovery and rapid high-throughput antibody reexpression, ideally positioning your options efficiently from the broadest sources. In addition, antigen-binding sequences can be reexpressed in multiple formats (bispecifics, Fc-silenced, ADC, etc.) to more fully illuminate how your program can be best situated early in the discovery process.

Stay On-Plan and On-Budget
Delivering an antibody therapeutic to market is getting harder — and more expensive — than ever. So Cellestive is specifically designed to remove antibody generation as a potential pinch point, pain point, or sticking point in your program. “Good science” and “a good spend” aren’t mutually exclusive with Cellestive, since there are no licenses, royalties, or milestone payments required; it’s strictly pay-as-you-go, with built-in pause points. Perhaps more important, you partner with a team that has focused exclusively on fit-for-purpose antibody discovery for 30 years, meaning every lesson learned in that rich history gets applied to your project.

.jpeg)
Get More Hits on Target
By pursuing hybridoma, memory B-cell, and plasma B-cell discovery pathways in parallel, we efficiently generate distinct candidate sets, freeing you from the innate limitations or biases present in any one of these pathways. Simply put, with Cellestive, you don’t have to sacrifice any single variable — specificity, diversity, affinity, etc. — in favor of another. Instead, the entire population is open to interrogation, yielding a deep pool of opportunities through streamlined processes that happen in unison, rather than in a back-to-back, serial fashion.

Screen Thoroughly and Rapidly
With a full immune repertoire at your disposal from any cell secreting an antibody, Cellestive makes merging sequence-based and function-based antibody screening possible. We combine output with paired heavy- and light-chain sequence recovery and rapid high-throughput antibody reexpression, ideally positioning your options efficiently from the broadest sources. In addition, antigen-binding sequences can be reexpressed in multiple formats (bispecifics, Fc-silenced, ADC, etc.) to more fully illuminate how your program can be best situated early in the discovery process.

Stay On-Plan and On-Budget
Delivering an antibody therapeutic to market is getting harder — and more expensive — than ever. So Cellestive is specifically designed to remove antibody generation as a potential pinch point, pain point, or sticking point in your program. “Good science” and “a good spend” aren’t mutually exclusive with Cellestive, since there are no licenses, royalties, or milestone payments required; it’s strictly pay-as-you-go, with built-in pause points. Perhaps more important, you partner with a team that has focused exclusively on fit-for-purpose antibody discovery for 30 years, meaning every lesson learned in that rich history gets applied to your project.
Plasma B-Cell Services
Through Cellestive, our clients can capitalize on our in-house access to a proprietary technology with the capacity to interrogate, in a single run, at least ten times more plasma B-cells than current competing technologies. We can screen antibodies against both soluble antigens and target cells simultaneously, while AI-driven screening software can rank hits, define multiple unique phenotypes, and prioritize the best clones for recovery. Plus, fast setup and processing time allows multiple ~1.5 million capillary chip runs in a single workday, making it ideal for your difficult targets that demand maximum throughput on a broad range of parameters.
Hybridoma Library Services
Our B-cell fusion and hybridoma generation capability immortalizes the immune response of a host by combining optimized fusion techniques and proprietary growth medium formulations, promoting diversity and stability within the resulting hybridomas. Single-cell sorting of true clones by flow cytometry both improves the fidelity of screening and expedites the discovery process, since no further sub-cloning is required. The Hybridoma Libraries we produce for you through Cellestive are designed to deliver enduring value: they’re cryopreserved to maximize efficiency and flexibility while also minimizing the overhead costs of future research.
Memory B-Cell Services
Cellestive’s memory B-cell approach allows clients to screen more events than our other pathways, delivering hits with the broadest range of specificity and affinity. In addition, it allows clients to leverage the multiplexing capacity of flow cytometry with a 3-laser, 11-color sorter capable of distinguishing and isolating multiple distinct phenotypes in parallel. In as little as four weeks, Cellestive’s memory B-cell pathway can deliver a set of candidates ready to move forward to NGS sequencing. What that means is a faster, richer path towards heretofore-unreachable therapeutic targets.
See the Science Behind Cellestive

6 min read
Cell Fusion: A trusted tool that can still be an enigma
“Mystery is at the heart of creativity. That, and surprise.” Julia Cameron

2 min read
The Promising Potential of CAR-T Therapy
Post-Show Perspectives: Next-Generation CAR and T Cell Therapies June 18-20, 201...

1 min read
Success Rate of Different Antibody Platforms for Drug Discovery
We are occasionally asked about the success rate of different antibody platforms...
Let’s Illuminate a Better Way Together
Cellestive gives our most discerning clients all the options they need to optimize their antibody discovery. So how will your stars align? Let’s initiate the Cellestive project and find out together.
Contact Us